Post
Limited innovation in the late-stage pipeline for insomnia
Insomnia is the most common sleep disorder, characterised by patient-reported difficulty with sleep initiation and/or sleep maintenance. According to the …
Regeneron’s linvoseltamab shows early and durable response in pre-treated MM
Regeneron Pharmaceuticals has presented Phase II data for linvoseltamab in patients with relapsed/refractory (r/r) multiple myeloma (MM) who have received …
Q&A: ‘Trial failure due to recruitment is a thing of the past thanks to AI’
One pain point for sponsors is trial termination due to lack of recruitment, partially a result of recruiting the wrong …
PercAssist implants first patient with extravascular cardiac assistance device
PercAssist has completed its first patient case in its First-in-Human clinical study investigating its Percutaneous Synchronised Cardiac Assist (PSCA) device …
Janssen’s NSCLC combo therapy meets primary endpoint in Phase III trial
The Janssen Pharmaceutical Companies of Johnson & Johnson has reported that the Phase III MARIPOSA clinical trial of Rybrevant (amivantamab-vmjw) …
PercAssist implants first patient with extravascular cardiac assistance device
PercAssist has completed its first patient case in its First-in-Human clinical study investigating its Percutaneous Synchronised Cardiac Assist (PSCA) device …
Janssen’s NSCLC combo therapy meets primary endpoint in Phase III trial
The Janssen Pharmaceutical Companies of Johnson & Johnson has reported that the Phase III MARIPOSA clinical trial of Rybrevant (amivantamab-vmjw) …
ImmunoGenesis begins participant dosing in trial of IMGS‑001
ImmunoGenesis has dosed the first participant in its Phase Ia/Ib clinical trial of IMGS-001 for the treatment of relapsed or refractory advanced …
Aleta aims for pivotal US trial with CAR T-cell engager
Aleta Biotherapeutics is working to initiate a potentially registrational trial in the US for its CAR T-cell therapy engager (CTE) …
Ascletis reports positive data from Phase IIb hepatitis B therapy trial
Ascletis Pharma has reported positive interim findings from an expansion cohort of the Phase IIb clinical trial of ASC22 (Envafolimab) being analysed …
Synthekine doses first subject in Phase Ib of solid tumours trial
Synthekine has dosed the first subject in the Phase Ib portion of a clinical trial of STK-012 to treat solid tumours. The open-label, …
FDA approves IDE for HYDRAFIL system in degenerative disc disease study
The US Food and Drug Administration (FDA) has granted ReGelTec an investigational device exemption (IDE) for the company’s HYDRAFIL system. The …
Another blow for Gilead after third magrolimab hit, upsetting $4.9bn deal
Gilead Sciences has been dealt another blow as it announces the termination of a second Phase III trial of acquired …
Circuit Clinical enters partnership to expand trial access
Integrated research organisation (IRO) Circuit Clinical has entered a partnership with Graves Gilbert and Labcorp to expand access to clinical trials for patients in South Central …
Janssen and Atropos partner to expedite clinical development
Johnson & Johnson company Janssen Research & Development has signed an agreement with Atropos Health to aid in expediting clinical development by …